What QDX does

QDX is a Singapore-based software company founded in 2023 that develops quantum chemistry simulation technology for drug discovery and materials science applications. Its core product, EXESS, is a proprietary quantum chemistry engine that performs over 1 quintillion calculations per second and operates 3,000 to 4,000 times faster than competing software without requiring quantum computing hardware, enabling large molecule calculations that were previously computationally infeasible. The engine applies optimization and generative AI techniques to predict molecular configurations and accelerate identification of drug candidates.

QDX operates a sales-led, enterprise-focused go-to-market targeting pharmaceutical and biotechnology companies through direct strategic partnerships and co-development agreements rather than traditional product distribution. Its primary customer segment is pharma/biotech firms seeking to compress drug discovery timelines. The company's revenue model appears to be licensing/royalty-based, tied to the progression of partnered drug programs. Its partnership with Prelude Therapeutics to study JAK2 V617F mutant-selective inhibitors for myeloproliferative neoplasms resulted in Incyte's acquisition of that program for up to $910 million, providing external validation of QDX's scientific and commercial approach. The company is privately held, employs 11-50 people, and is led by founder/CEO Loong Wang.

Name

QDX

Legal name

QDX

Website

https://qdx.co

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

QDX is a Singapore-based quantum chemistry software company whose EXESS engine performs over 1 quintillion molecular calculations per second for pharmaceutical and biotech drug discovery partners. The company serves pharma and biotech firms via licensing and strategic co-development agreements, with Prelude Therapeutics and the Incyte $910M acquisition as key validation signals.

Ownership category

akta.pro rank

Product category

Computational Chemistry / Drug Discovery Software

NAICS

Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Computer Programming Services (7371)

akta.pro primary industry

Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB)

akta.pro secondary industries

Quantum Simulation (Physics/Chemistry/Materials) Research (HDAGAMAG), Quantum Machine Learning (QML) (HDAGADAC)

Keywords

• Quantum chemistry software
• Drug discovery simulation
• Molecular modeling platform
• Computational chemistry engine
• Pharma R&D software

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Quantum Chemistry Simulation Services: QDX provides quantum chemistry simulation technology to pharmaceutical and biotech partners for drug discovery applications. Revenue appears to come from strategic partnerships and co-development agreements with drug companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

QDX develops and licenses EXESS, a proprietary quantum chemistry simulation engine that performs over 1 quintillion calculations per second on classical computing infrastructure. The platform enables pharmaceutical and biotech researchers to run large-molecule calculations 3,000 to 4,000 times faster than competing quantum chemistry software without requiring quantum computing hardware, accelerating drug discovery and materials science research.

Product overview

QDX offers a single core product: EXESS, an ultrafast quantum chemistry engine designed specifically for drug discovery applications. The platform enables pharmaceutical researchers to perform large-scale molecular calculations at speeds 3,000 to 4,000 times faster than conventional software, without the need for quantum computing infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

• EXESS Quantum Chemistry Engine EXESS is an ultrafast proprietary quantum chemistry simulation engine for pharmaceutical and biotechnology researchers, performing over 1 quintillion calculations per second on classical infrastructure and enabling large-molecule calculations 3,000 to 4,000 times faster than competing software for drug discovery and materials science applications.

Quantifiable outcome

• Performs over 1 quintillion calculations per second
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

Two partnerships are on record, tiered core and minor.

• Prelude TherapeuticscoreStrategic or Co-development Partner · 4 December 2025QDX partnered with Prelude Therapeutics to apply quantum chemistry simulations to cancer drug discovery. The collaboration focused on studying structural differences in JAK2 V617F mutant proteins to develop selective inhibitors for treating myeloproliferative neoplasms (MPNs). This partnership resulted in Prelude's JAK2V617F program being acquired by Incyte for up to $910 million, validating the scientific approach.
• IncyteminorOthersIncyte acquired Prelude's JAK2V617F program, which was developed using QDX's quantum chemistry simulations. While not a direct partnership with QDX, Incyte's $910M acquisition validates the effectiveness of QDX-enabled drug discovery.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Schrödinger: Schrödinger provides computational chemistry and molecular simulation software widely used in pharma drug discovery. It is the most established direct competitor to QDX in quantum chemistry and molecular simulation software for pharmaceutical R&D.
• Multiverse Computing: Multiverse Computing applies quantum and quantum-inspired algorithms to pharma, materials, and finance. Its Singularity/Quantum Pharma tools overlap directly with QDX's pharma drug discovery simulation use case.
• QC Ware: QC Ware builds quantum and quantum-inspired software for chemistry, materials, and machine learning, with a similar pharma/biotech customer focus to QDX.
• QunaSys: QunaSys develops quantum chemistry algorithms and software (Qamuy, etc.) for chemical and pharmaceutical applications. It is a direct competitor to QDX in applying quantum algorithms to drug discovery and materials science.

Emerging players

• Zapata AI: Zapata AI develops quantum-inspired generative AI and optimization algorithms for enterprise use cases including pharma and materials, making it a partial overlap with QDX's quantum chemistry simulation plus generative AI stack.
• Xanadu: Xanadu builds photonic quantum hardware and the PennyLane software platform for quantum chemistry and quantum machine learning, overlapping with QDX's drug discovery and QML capability areas.

Broad incumbents

• Google Quantum AI: Google Quantum AI develops superconducting quantum hardware and has published landmark quantum chemistry simulations. It represents the long-term hardware-based competitive threat to QDX's classical approach.
• Quantinuum: Quantinuum combines trapped-ion quantum hardware (H-Series) with chemistry simulation software (InQuanto). It is a broader quantum computing incumbent competing with QDX in the quantum chemistry for pharma space.
• PsiQuantum: PsiQuantum is pursuing fault-tolerant photonic quantum computing, with chemistry simulations as a key target application. It represents a longer-term competitive force for the broader quantum chemistry simulation market.
• IBM Quantum: IBM Quantum offers quantum hardware and Qiskit-based chemistry tools widely used in pharma R&D. It is a broad incumbent in the quantum chemistry space where QDX competes with a classical-algorithm alternative.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QDX